.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Accenture
Colorcon
Chinese Patent Office
McKesson
Argus Health
Cantor Fitzgerald
Healthtrust
Dow
US Department of Justice

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Optimized and defined method for isolation and preservation of precursor cells from human umbilical cord
Abstract: The present invention refers to an optimized and defined method for isolation and preservation of precursor cells from human umbilical cord. Besides being reproducible and 100% reliable, in terms of the number of samples processed, the method results in a high and defined number of precursor cells, being the majority obtained after a single adhesion and expansion/multiplication phase ex vivo (thus granting cell phenotype), in a shorter time frame than what was previously described in the state-of-the-art. With this method, it is possible to obtain, in 9 days, after direct freezing of a cell fraction, and after one expansion/multiplication phase ex vivo (end of P0) of the majority of the cells, about 8.6(.+-.0.1).times.10.sup.5 cells/gram of processed umbilical cord. In turn, the characteristics of the cells allow, for example, after 35 days, obtaining an average of 7.7.times.10.sup.15 cells, with precursor phenotype, from 100% of processed umbilical cord samples. The method, because it is simple, robust and 100% reliable, can be performed under good manufacturing practices (GMP) in laboratories dedicated to cell therapy in humans. Furthermore, the method has applications in the pharmaceutical, cosmetic and biotechnology areas.
Inventor(s): Ganchas Soares; Rita Isabel (Oeiras, PT), Baptista Coelho; Maria Constanca (Oeiras, PT), Silva Santos; Jorge Miguel (Oeiras, PT), Martins; Jose Paulo (Oeiras, PT), Basto; Vera Alexandra (Oeiras, PT), Estilita Monteiro Da Cruz; Pedro (Oeiras, PT), Soares Da Cruz; Helder Joaquim (Oeiras, PT)
Assignee: Laboratorio Medinfar-Produtos Farmaceuticos, S.A. (Amadora, PT)
Application Number:12/680,604
Patent Claims:1. A method of recovering precursor cells from an umbilical cord, said method comprising: a) providing a portion of an umbilical cord from which the amniotic membrane has been removed but from which umbilical cord vessels have not been extracted, and which has not been subjected to maceration nor crushing of tissues in the sub-amniotic, intervascular, and perivascular regions of said portion of umbilical cord; b) digesting said portion of umbilical cord in a first flask with an enzymatic digestion solution under conditions for digesting the umbilical cord tissue of said portion of umbilical cord, without digesting said umbilical cord vessels; and c) after said digesting step, collecting cells in three isolation phases: (i) a first isolation phase comprising collecting cells that adhere to said first flask after standing at least 5 minutes after said digesting step; (ii) a second isolation phase comprising collecting cells that adhere to a second flask from a supernatant, said supernatant generated by centrifuging said enzymatic digestion solution after said digesting step and after said first isolation phase; and (iii) a third isolation phase comprising collecting cells from the pellet generated by centrifuging said enzymatic digestion solution after said digesting step and after said first isolation phase; thereby recovering precursor cells that can demonstrate osteogenic, chondrogenic, adipogenic, cardiomyogenic, and glial/neurogenic differentiation.

2. The method according to claim 1, wherein said umbilical cord is a human umbilical cord.

3. The method according to claim 1, wherein said portion has been cut transversally and/or from which blood clots have been removed.

4. The method according to claim 1, wherein said enzymatic digestion solution comprises collagenase and trypsin.

5. The method according to claim 4, wherein said enzymatic digestion solution comprises 0.0375-0.075% collagenase II (w/v) and 0.125% trypsin (w/v).

6. The method according to claim 1, wherein said first flask has dimensions providing a ratio of about 1:2:2:37 for umbilical cord tissue mass (g) to bottom surface area of said first flask (cm.sup.2) to volume of said enzymatic digestion solution (mL) to total volume of said first flask (mL).

7. The method according to claim 1, wherein said digestion step further comprises agitation of about 100 oscillations/minute, in a dry atmosphere.

8. The method according to claim 1, wherein said digestion is performed under conditions that maintain a pH of 6.4 or higher of said enzymatic digestion solution.

9. The method according to claim 1, wherein the digestion is performed for 2-16 hours.

10. The method according to claim 9, wherein the digestion is performed for about 4 hours.

11. The method according to claim 1, wherein said precursor cells collected in phase (i) are collected following a period of standing of 5 to 300 minutes after the end of said digestion.

12. The method according to claim 1, wherein said precursor cells collected in phase (i) are cultured for one round of expansion, before being collected.

13. The method according to claim 12, wherein said precursor cells collected in phase (i) are cultured to confluence during said expansion, before being collected.

14. The method according to claim 1, wherein said precursor cells collected in phase (ii) are cultured for one round of expansion, before being collected.

15. The method according to claim 14, wherein said precursor cells collected in phase (ii) are cultured to confluence during said expansion, before being collected.

16. The method according to claim 1 wherein at least 8.times.10.sup.5 precursor cells are recovered per gram of umbilical cord provided.

17. The method according to claim 1 wherein said method allows 100% efficacy in providing precursor cells for each umbilical cord used.

18. The method according to claim 1, further comprising the step of cryopreservation of said recovered precursor cells.

19. The method according to claim 18, wherein the density of said precursor cells after cryopreservation is about 3.times.10.sup.6 cells/mL.

Summary for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Portugal103843Oct 4, 2007
PCT Information
PCT FiledOctober 03, 2008PCT Application Number:PCT/IB2008/054067
PCT Publication Date:April 09, 2009PCT Publication Number: WO2009/044379

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Advance Biofactures
SANTYL
collagenase
VIAL1019950011965-06-04► Subscribe Laboratorio Medinfar-Produtos Farmaceuticos, S.A. (Amadora, PT) Ganchas Soares; Rita Isabel (Oeiras, PT), Baptista Coelho; Maria Constanca (Oeiras, PT), Silva Santos; Jorge Miguel (Oeiras, PT), Martins; Jose Paulo (Oeiras, PT), Basto; Vera Alexandra (Oeiras, PT), Estilita Monteiro Da Cruz; Pedro (Oeiras, PT), Soares Da Cruz; Helder Joaquim (Oeiras, PT) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Boehringer Ingelheim
Cantor Fitzgerald
Queensland Health
Mallinckrodt
McKinsey
US Army
Argus Health
AstraZeneca
Fuji
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot